A Randomized Trial of Bictegravir or Dolutegravir with Emtricitabine and Tenofovir Alafenamide (F/TAF) Followed by Open Label Switch to Bictegravir/F/TAF Fixed Dose Combination

BACKGROUND: Integrase strand transfer inhibitors (INSTIs) are widely recommended for initial HIV-1 treatment. Bictegravir (BIC, B) is a novel, once-daily INSTI with potent antiviral activity being developed in coformulation with emtricitabine and tenofovir alafenamide (F/TAF). METHODS: In this Phase...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Open Forum Infect Dis
Autori principali: Sax, Paul E, Dejesus, Edwin, Crofoot, Gordon, Ward, Douglas, Benson, Paul, Wei, Lilian, White, Kirsten, Collins, Sean, Martin, Hal, Cheng, Andrew, Quirk, Erin
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2017
Soggetti:
Abstracts
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5630742/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofx163.1076
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi